Patient characteristics at the time of starting 2G-TKI and 2.5-year probabilities of EFS, PFS, and OS*
| Variable . | n . | EFS, % . | PFS, % . | Survival, % . |
|---|---|---|---|---|
| Age, y | P = .84 | P = .86 | P = .77 | |
| > 55 | 40 | 84.5 | 87.6 | 91.8 |
| ≤ 55 | 35 | 87.2 | 89.9 | 89.2 |
| Sex | P = .13 | P = .11 | P = .37 | |
| Male | 35 | 80.6 | 82.7 | 88.4 |
| Female | 40 | 91.5 | 94.8 | 92.6 |
| Sokal risk group | P = .65 | P = .77 | P = .28 | |
| Low | 15 | 92.3 | 92.3 | 100 |
| Intermediate | 29 | 82.2 | 85.9 | 83.2 |
| High | 31 | 86.4 | 89.8 | 93.5 |
| Status at the onset of imatinib therapy | P = .8 | P = .94 | P = .48 | |
| Newly diagnosed CP patients | 28 | 85.1 | 89.1 | 86.1 |
| Late CP | 47 | 86.7 | 89.0 | 93.2 |
| Additional cytogenetic abnormalities at start of 2G-TKI | P = .17 | P = .44 | P = .25 | |
| No | 63 | 88.3 | 90.0 | 92.5 |
| Yes | 12 | 74.1 | 83.3 | 81.5 |
| Percentage of Ph-positive marrow metaphases at start of 2G-TKI | P = .064 | P = .14 | P = .29 | |
| < 95% | 28 | 96.4 | 95.2 | 96.4 |
| ≥ 95% | 47 | 79.9 | 84.5 | 87.9 |
| Time from imatinib failure to starting 2G-TKI | P = .42 | P = .60 | P = .84 | |
| ≤ 6 months | 15 | 93.3 | 93.3 | 90.9 |
| > 6 months | 60 | 84.2 | 87.8 | 90.5 |
| Best cytogenetic response on imatinib† | P = .002 | P = .043 | P = .017 | |
| 0%-94% Ph+ | 42 | 63.7 | 76.5 | 75.3 |
| ≥ 95% Ph+ | 33 | 92.6 | 92.6 | 96.4 |
| Hematologic resistance to imatinib | P = .29 | P = .44 | P = .78 | |
| Yes | 55 | 79.7 | 90.3 | 89.5 |
| No | 20 | 88.3 | 85.0 | 91.4 |
| Maximal dose of imatinib | P = .55 | P = .68 | P = .82 | |
| 400 mg/day | 16 | 93.8 | 93.8 | 93.8 |
| 600 mg/day | 29 | 81.5 | 85.4 | 87.9 |
| 800 mg/day | 30 | 86.2 | 89.8 | 92.0 |
| KD mutation at start of 2G-TKI | P = .51 | P = .31 | P = .11 | |
| No | 55 | 84.9 | 86.9 | 100 |
| Yes | 20 | 90.0 | 95.0 | 86.7 |
| Transcript type | P = .57 | P = .62 | P = .72 | |
| e14a2 | 26 | 83.9 | 83.9 | 86.3 |
| e13a2 | 34 | 91.1 | 91.1 | 93.2 |
| e14a2 and e13a2 | 15 | 78.3 | 93.3 | 93.3 |
| EVI-1 at start of 2G-TKI | P = .0001 | P < .0001 | P = .0003 | |
| Negative | 67 | 90.6 | 93.8 | 95.2 |
| Positive | 8 | 43.7 | 43.7 | 47.5 |
| Percentage of blasts in bone marrow at start of 2G-TKI | P = .02 | P = .1 | P = .3 | |
| ≤ 5% | 54 | 90.4 | 88.4 | 90.4 |
| > 5% | 21 | 66.7 | 77.1 | 83.8 |
| Hemoglobin level at start of 2G-TKI† | P = .3 | P = .5 | P = .5 | |
| Normal | 41 | 92.8 | 92.9 | 96.4 |
| Low | 34 | 82.3 | 86.7 | 89.6 |
| Variable . | n . | EFS, % . | PFS, % . | Survival, % . |
|---|---|---|---|---|
| Age, y | P = .84 | P = .86 | P = .77 | |
| > 55 | 40 | 84.5 | 87.6 | 91.8 |
| ≤ 55 | 35 | 87.2 | 89.9 | 89.2 |
| Sex | P = .13 | P = .11 | P = .37 | |
| Male | 35 | 80.6 | 82.7 | 88.4 |
| Female | 40 | 91.5 | 94.8 | 92.6 |
| Sokal risk group | P = .65 | P = .77 | P = .28 | |
| Low | 15 | 92.3 | 92.3 | 100 |
| Intermediate | 29 | 82.2 | 85.9 | 83.2 |
| High | 31 | 86.4 | 89.8 | 93.5 |
| Status at the onset of imatinib therapy | P = .8 | P = .94 | P = .48 | |
| Newly diagnosed CP patients | 28 | 85.1 | 89.1 | 86.1 |
| Late CP | 47 | 86.7 | 89.0 | 93.2 |
| Additional cytogenetic abnormalities at start of 2G-TKI | P = .17 | P = .44 | P = .25 | |
| No | 63 | 88.3 | 90.0 | 92.5 |
| Yes | 12 | 74.1 | 83.3 | 81.5 |
| Percentage of Ph-positive marrow metaphases at start of 2G-TKI | P = .064 | P = .14 | P = .29 | |
| < 95% | 28 | 96.4 | 95.2 | 96.4 |
| ≥ 95% | 47 | 79.9 | 84.5 | 87.9 |
| Time from imatinib failure to starting 2G-TKI | P = .42 | P = .60 | P = .84 | |
| ≤ 6 months | 15 | 93.3 | 93.3 | 90.9 |
| > 6 months | 60 | 84.2 | 87.8 | 90.5 |
| Best cytogenetic response on imatinib† | P = .002 | P = .043 | P = .017 | |
| 0%-94% Ph+ | 42 | 63.7 | 76.5 | 75.3 |
| ≥ 95% Ph+ | 33 | 92.6 | 92.6 | 96.4 |
| Hematologic resistance to imatinib | P = .29 | P = .44 | P = .78 | |
| Yes | 55 | 79.7 | 90.3 | 89.5 |
| No | 20 | 88.3 | 85.0 | 91.4 |
| Maximal dose of imatinib | P = .55 | P = .68 | P = .82 | |
| 400 mg/day | 16 | 93.8 | 93.8 | 93.8 |
| 600 mg/day | 29 | 81.5 | 85.4 | 87.9 |
| 800 mg/day | 30 | 86.2 | 89.8 | 92.0 |
| KD mutation at start of 2G-TKI | P = .51 | P = .31 | P = .11 | |
| No | 55 | 84.9 | 86.9 | 100 |
| Yes | 20 | 90.0 | 95.0 | 86.7 |
| Transcript type | P = .57 | P = .62 | P = .72 | |
| e14a2 | 26 | 83.9 | 83.9 | 86.3 |
| e13a2 | 34 | 91.1 | 91.1 | 93.2 |
| e14a2 and e13a2 | 15 | 78.3 | 93.3 | 93.3 |
| EVI-1 at start of 2G-TKI | P = .0001 | P < .0001 | P = .0003 | |
| Negative | 67 | 90.6 | 93.8 | 95.2 |
| Positive | 8 | 43.7 | 43.7 | 47.5 |
| Percentage of blasts in bone marrow at start of 2G-TKI | P = .02 | P = .1 | P = .3 | |
| ≤ 5% | 54 | 90.4 | 88.4 | 90.4 |
| > 5% | 21 | 66.7 | 77.1 | 83.8 |
| Hemoglobin level at start of 2G-TKI† | P = .3 | P = .5 | P = .5 | |
| Normal | 41 | 92.8 | 92.9 | 96.4 |
| Low | 34 | 82.3 | 86.7 | 89.6 |
P values were calculated using the log-rank method. Variables with a P value < .1 were included in the multivariate analysis for each outcome.
Other peripheral blood and bone marrow parameters are not included in the table, but they did not significantly predict for any of the outcomes.
Normal values are > 12.5 for males and > 11.5 for females.